Compile Data Set for Download or QSAR

Found 162 hits Enz. Inhib. hit(s) with all data for entry = 7831   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221600 (US9303045, 87 | US9695195, 87) Show SMILES CN1C2CCCC1CC(C2)OC(=O)c1cn(CCF)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C20H25FN2O2/c1-22-14-5-4-6-15(22)12-16(11-14)25-20(24)18-13-23(10-9-21)19-8-3-2-7-17(18)19/h2-3,7-8,13-16H,4-6,9-12H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.180	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221544 (US9303045, 30 | US9695195, 30) Show SMILES CN1C2CCCC1CC(C2)OC(=O)c1c(Cl)n(CCF)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C20H24ClFN2O2/c1-23-13-5-4-6-14(23)12-15(11-13)26-20(25)18-16-7-2-3-8-17(16)24(10-9-22)19(18)21/h2-3,7-8,13-15H,4-6,9-12H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221601 (US9303045, 88 | US9695195, 88) Show SMILES CN1C2CCCC1CC(C2)OC(=O)c1c(C)n(CCF)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H27FN2O2/c1-14-20(18-8-3-4-9-19(18)24(14)11-10-22)21(25)26-17-12-15-6-5-7-16(13-17)23(15)2/h3-4,8-9,15-17H,5-7,10-13H2,1-2H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.220	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221592 (US9303045, 127 | US9303045, 79 | US9695195, 127) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(CCF)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H24FN3O2/c1-22-14-8-13(9-15(22)12-25-11-14)21-19(24)17-10-23(7-6-20)18-5-3-2-4-16(17)18/h2-5,10,13-15H,6-9,11-12H2,1H3,(H,21,24)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.220	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221622 (US9303045, 113 | US9695195, 113) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(CC(F)F)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H23F2N3O2/c1-23-13-6-12(7-14(23)11-26-10-13)22-19(25)16-8-24(9-18(20)21)17-5-3-2-4-15(16)17/h2-5,8,12-14,18H,6-7,9-11H2,1H3,(H,22,25)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.230	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221572 (US9303045, 58 | US9695195, 58) Show SMILES CN1C2COCC1CC(C2)OC(=O)c1cn(CC(F)F)c2ccc(F)cc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H21F3N2O3/c1-23-12-5-14(6-13(23)10-26-9-12)27-19(25)16-7-24(8-18(21)22)17-3-2-11(20)4-15(16)17/h2-4,7,12-14,18H,5-6,8-10H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.240	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221624 (US9303045, 117 | US9303045, 123 | US9695195, 123) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cccnn2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H23N5O2/c1-25-15-9-14(10-16(25)13-28-12-15)23-21(27)18-11-26(20-7-4-8-22-24-20)19-6-3-2-5-17(18)19/h2-8,11,14-16H,9-10,12-13H2,1H3,(H,23,27)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.280	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221610 (US9303045, 99 | US9695195, 99) Show SMILES CN1C2COCC1CC(C2)OC(=O)c1cn(c2ccc(F)cc12)S(C)(=O)=O |THB:10:8:1:3.5.4| Show InChI InChI=1S/C18H21FN2O5S/c1-20-12-6-14(7-13(20)10-25-9-12)26-18(22)16-8-21(27(2,23)24)17-4-3-11(19)5-15(16)17/h3-5,8,12-14H,6-7,9-10H2,1-2H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.290	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221654 (US9303045, 159 | US9695195, 159) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(CC#N)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H22N4O2/c1-22-14-8-13(9-15(22)12-25-11-14)21-19(24)17-10-23(7-6-20)18-5-3-2-4-16(17)18/h2-5,10,13-15H,7-9,11-12H2,1H3,(H,21,24)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.298	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221651 (US9303045, 154 | US9695195, 154) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cncn2C)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H25N5O2/c1-24-13-22-9-20(24)26-10-18(17-5-3-4-6-19(17)26)21(27)23-14-7-15-11-28-12-16(8-14)25(15)2/h3-6,9-10,13-16H,7-8,11-12H2,1-2H3,(H,23,27)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.328	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221561 (US9303045, 47 | US9695195, 47) Show SMILES CN1C2COCC1CC(C2)OC(=O)c1cn(c2ccccc12)S(C)(=O)=O |THB:10:8:1:3.5.4| Show InChI InChI=1S/C18H22N2O5S/c1-19-12-7-14(8-13(19)11-24-10-12)25-18(21)16-9-20(26(2,22)23)17-6-4-3-5-15(16)17/h3-6,9,12-14H,7-8,10-11H2,1-2H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.330	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221627 (US9303045, 120 | US9695195, 120) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cncnc2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H23N5O2/c1-25-15-6-14(7-16(25)12-28-11-15)24-21(27)19-10-26(17-8-22-13-23-9-17)20-5-3-2-4-18(19)20/h2-5,8-10,13-16H,6-7,11-12H2,1H3,(H,24,27)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.390	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221624 (US9303045, 117 | US9303045, 123 | US9695195, 123) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cccnn2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H23N5O2/c1-25-15-9-14(10-16(25)13-28-12-15)23-21(27)18-11-26(20-7-4-8-22-24-20)19-6-3-2-5-17(18)19/h2-8,11,14-16H,9-10,12-13H2,1H3,(H,23,27)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.390	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221649 (US9303045, 148) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cncs2)c2ncccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H21N5O2S/c1-23-13-5-12(6-14(23)10-26-9-13)22-19(25)16-8-24(17-7-20-11-27-17)18-15(16)3-2-4-21-18/h2-4,7-8,11-14H,5-6,9-10H2,1H3,(H,22,25)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221535 (US9303045, 20 | US9695195, 20) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1nn(CC(F)F)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C18H22F2N4O2/c1-23-12-6-11(7-13(23)10-26-9-12)21-18(25)17-14-4-2-3-5-15(14)24(22-17)8-16(19)20/h2-5,11-13,16H,6-10H2,1H3,(H,21,25)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221626 (US9303045, 119 | US9695195, 148) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cncs2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C20H22N4O2S/c1-23-14-6-13(7-15(23)11-26-10-14)22-20(25)17-9-24(19-8-21-12-27-19)18-5-3-2-4-16(17)18/h2-5,8-9,12-15H,6-7,10-11H2,1H3,(H,22,25)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221648 (US9303045, 147 | US9695195, 147) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cscn2)c2ncccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H21N5O2S/c1-23-13-5-12(6-14(23)9-26-8-13)22-19(25)16-7-24(17-10-27-11-21-17)18-15(16)3-2-4-20-18/h2-4,7,10-14H,5-6,8-9H2,1H3,(H,22,25)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221679 (US9303045, 21) Show SMILES FC(F)Cn1cc(C(=O)NC2CC3COCC(C2)N3)c2ccccc12 |TLB:9:10:18:13.15.14| Show InChI InChI=1S/C18H21F2N3O2/c19-17(20)8-23-7-15(14-3-1-2-4-16(14)23)18(24)22-11-5-12-9-25-10-13(6-11)21-12/h1-4,7,11-13,17,21H,5-6,8-10H2,(H,22,24)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221592 (US9303045, 127 | US9303045, 79 | US9695195, 127) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(CCF)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H24FN3O2/c1-22-14-8-13(9-15(22)12-25-11-14)21-19(24)17-10-23(7-6-20)18-5-3-2-4-16(17)18/h2-5,10,13-15H,6-9,11-12H2,1H3,(H,21,24)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.410	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221644 (US9303045, 143 | US9695195, 143) Show SMILES O=C(OC1CC2COCC(C1)N2)c1cn(-c2cnsc2)c2ccccc12 |TLB:2:3:11:6.8.7| Show InChI InChI=1S/C19H19N3O3S/c23-19(25-15-5-12-9-24-10-13(6-15)21-12)17-8-22(14-7-20-26-11-14)18-4-2-1-3-16(17)18/h1-4,7-8,11-13,15,21H,5-6,9-10H2	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.415	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221587 (US9303045, 74 | US9695195, 74) Show SMILES CN1C2CCC1CC(C2)NC(=O)c1cn(c2ccccc12)S(C)(=O)=O |THB:9:7:1:3.4| Show InChI InChI=1S/C18H23N3O3S/c1-20-13-7-8-14(20)10-12(9-13)19-18(22)16-11-21(25(2,23)24)17-6-4-3-5-15(16)17/h3-6,11-14H,7-10H2,1-2H3,(H,19,22)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.420	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221574 (US9303045, 60 | US9695195, 60) Show SMILES CN1C2CCCC1CC(C2)OC(=O)c1cn(CC(F)F)c2ccc(F)cc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C20H23F3N2O2/c1-24-13-3-2-4-14(24)9-15(8-13)27-20(26)17-10-25(11-19(22)23)18-6-5-12(21)7-16(17)18/h5-7,10,13-15,19H,2-4,8-9,11H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.440	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221527 (US9303045, 12 | US9695195, 12) Show SMILES CN1C2CCCC1CC(C2)NC(=O)c1nn(CCF)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H25FN4O/c1-23-14-5-4-6-15(23)12-13(11-14)21-19(25)18-16-7-2-3-8-17(16)24(22-18)10-9-20/h2-3,7-8,13-15H,4-6,9-12H2,1H3,(H,21,25)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.450	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221677 (US9303045, 189 | US9695195, 189) Show SMILES CN1C2COCC1CC(C2)OC(=O)c1cn(-c2cncnc2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H22N4O3/c1-24-14-6-17(7-15(24)12-27-11-14)28-21(26)19-10-25(16-8-22-13-23-9-16)20-5-3-2-4-18(19)20/h2-5,8-10,13-15,17H,6-7,11-12H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.460	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221577 (US9303045, 63 | US9695195, 63) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(CC(F)F)c2ccc(F)cc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H22F3N3O2/c1-24-13-5-12(6-14(24)10-27-9-13)23-19(26)16-7-25(8-18(21)22)17-3-2-11(20)4-15(16)17/h2-4,7,12-14,18H,5-6,8-10H2,1H3,(H,23,26)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.490	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221523 (US9303045, 7 | US9695195, 7) Show SMILES CN1C2CCCC1CC(C2)NC(=O)c1nn(CC(F)F)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H24F2N4O/c1-24-13-5-4-6-14(24)10-12(9-13)22-19(26)18-15-7-2-3-8-16(15)25(23-18)11-17(20)21/h2-3,7-8,12-14,17H,4-6,9-11H2,1H3,(H,22,26)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.490	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221550 (US9303045, 36 | US9695195, 36) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(c2ccc(F)cc12)S(C)(=O)=O |THB:10:8:1:3.5.4| Show InChI InChI=1S/C18H22FN3O4S/c1-21-13-6-12(7-14(21)10-26-9-13)20-18(23)16-8-22(27(2,24)25)17-4-3-11(19)5-15(16)17/h3-5,8,12-14H,6-7,9-10H2,1-2H3,(H,20,23)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221530 (US9303045, 15 | US9695195, 15) Show SMILES CN1C2CCC1CC(C2)OC(=O)c1c(C)n(CCF)c2ccccc12 |THB:9:7:1:3.4| Show InChI InChI=1S/C20H25FN2O2/c1-13-19(17-5-3-4-6-18(17)23(13)10-9-21)20(24)25-16-11-14-7-8-15(12-16)22(14)2/h3-6,14-16H,7-12H2,1-2H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.530	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221524 (US9303045, 112 | US9303045, 8 | US9695195, 112) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(CC(F)(F)F)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H22F3N3O2/c1-24-13-6-12(7-14(24)10-27-9-13)23-18(26)16-8-25(11-19(20,21)22)17-5-3-2-4-15(16)17/h2-5,8,12-14H,6-7,9-11H2,1H3,(H,23,26)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.530	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221570 (US9303045, 56 | US9695195, 56) Show SMILES CN1C2CCC1CC(C2)OC(=O)c1cn(CCF)c2ccccc12 |THB:9:7:1:3.4| Show InChI InChI=1S/C19H23FN2O2/c1-21-13-6-7-14(21)11-15(10-13)24-19(23)17-12-22(9-8-20)18-5-3-2-4-16(17)18/h2-5,12-15H,6-11H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.530	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221540 (US9303045, 26 | US9695195, 26) Show SMILES CN1C2CCC1CC(C2)OC(=O)c1cn(c2ccccc12)S(C)(=O)=O |THB:9:7:1:3.4| Show InChI InChI=1S/C18H22N2O4S/c1-19-12-7-8-13(19)10-14(9-12)24-18(21)16-11-20(25(2,22)23)17-6-4-3-5-15(16)17/h3-6,11-14H,7-10H2,1-2H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.540	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221549 (US9303045, 35 | US9695195, 35) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(CC(F)(F)F)c2ccc(F)cc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H21F4N3O2/c1-25-13-5-12(6-14(25)9-28-8-13)24-18(27)16-7-26(10-19(21,22)23)17-3-2-11(20)4-15(16)17/h2-4,7,12-14H,5-6,8-10H2,1H3,(H,24,27)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.540	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221633 (US9303045, 129 | US9303045, 130 | US9695195, 130) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cnccn2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H23N5O2/c1-25-15-8-14(9-16(25)13-28-12-15)24-21(27)18-11-26(20-10-22-6-7-23-20)19-5-3-2-4-17(18)19/h2-7,10-11,14-16H,8-9,12-13H2,1H3,(H,24,27)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.550	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221526 (US9303045, 10 | US9303045, 111 | US9695195, 111) Show SMILES CC(C)S(=O)(=O)n1cc(C(=O)NC2CC3COCC(C2)N3C)c2ccccc12 |TLB:11:12:20:15.17.16| Show InChI InChI=1S/C20H27N3O4S/c1-13(2)28(25,26)23-10-18(17-6-4-5-7-19(17)23)20(24)21-14-8-15-11-27-12-16(9-14)22(15)3/h4-7,10,13-16H,8-9,11-12H2,1-3H3,(H,21,24)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.570	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221560 (US9303045, 46 | US9695195, 46) Show SMILES CN1C2CCCC1CC(C2)NC(=O)c1nn(c2ccccc12)S(C)(=O)=O |THB:10:8:1:3.5.4| Show InChI InChI=1S/C18H24N4O3S/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(20-17)26(2,24)25/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.590	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221662 (US9303045, 169 | US9695195, 169) Show SMILES CN1C2COCC1CC(C2)OC(=O)c1cn(-c2ccc(O)nn2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H22N4O4/c1-24-13-8-15(9-14(24)12-28-11-13)29-21(27)17-10-25(18-5-3-2-4-16(17)18)19-6-7-20(26)23-22-19/h2-7,10,13-15H,8-9,11-12H2,1H3,(H,23,26)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.598	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221565 (US9303045, 51) Show SMILES CN1C2COCC1CC(C2)OC(=O)c1cn(CCF)c2ncccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C18H22FN3O3/c1-21-12-7-14(8-13(21)11-24-10-12)25-18(23)16-9-22(6-4-19)17-15(16)3-2-5-20-17/h2-3,5,9,12-14H,4,6-8,10-11H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221645 (US9303045, 144 | US9695195, 144) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cnsc2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C20H22N4O2S/c1-23-14-6-13(7-15(23)11-26-10-14)22-20(25)18-9-24(16-8-21-27-12-16)19-5-3-2-4-17(18)19/h2-5,8-9,12-15H,6-7,10-11H2,1H3,(H,22,25)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.610	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221633 (US9303045, 129 | US9303045, 130 | US9695195, 130) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cnccn2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H23N5O2/c1-25-15-8-14(9-16(25)13-28-12-15)24-21(27)18-11-26(20-10-22-6-7-23-20)19-5-3-2-4-17(18)19/h2-7,10-11,14-16H,8-9,12-13H2,1H3,(H,24,27)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.640	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221602 (US9303045, 89 | US9695195, 89) Show SMILES CN1C2CCCC1CC(C2)OC(=O)c1cn(CC(F)(F)F)c2ccc(F)cc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C20H22F4N2O2/c1-25-13-3-2-4-14(25)9-15(8-13)28-19(27)17-10-26(11-20(22,23)24)18-6-5-12(21)7-16(17)18/h5-7,10,13-15H,2-4,8-9,11H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.660	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221524 (US9303045, 112 | US9303045, 8 | US9695195, 112) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(CC(F)(F)F)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H22F3N3O2/c1-24-13-6-12(7-14(24)10-27-9-13)23-18(26)16-8-25(11-19(20,21)22)17-5-3-2-4-15(16)17/h2-5,8,12-14H,6-7,9-11H2,1H3,(H,23,26)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.680	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221641 (US9303045, 137 | US9695195, 137) Show SMILES CN1C2COCC1CC(C2)OC(=O)c1cn(-c2ccc(F)nn2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H21FN4O3/c1-25-13-8-15(9-14(25)12-28-11-13)29-21(27)17-10-26(18-5-3-2-4-16(17)18)20-7-6-19(22)23-24-20/h2-7,10,13-15H,8-9,11-12H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.681	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221647 (US9303045, 146 | US9695195, 146) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2nccs2)c2ncccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H21N5O2S/c1-23-13-7-12(8-14(23)11-26-10-13)22-18(25)16-9-24(19-21-5-6-27-19)17-15(16)3-2-4-20-17/h2-6,9,12-14H,7-8,10-11H2,1H3,(H,22,25)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.702	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221548 (US9303045, 34 | US9695195, 34) Show SMILES CN1C2CCCC1CC(C2)OC(=O)c1cn(c2ccc(F)cc12)S(C)(=O)=O |THB:10:8:1:3.5.4| Show InChI InChI=1S/C19H23FN2O4S/c1-21-13-4-3-5-14(21)10-15(9-13)26-19(23)17-11-22(27(2,24)25)18-7-6-12(20)8-16(17)18/h6-8,11,13-15H,3-5,9-10H2,1-2H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.740	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221655 (US9303045, 160 | US9695195, 160) Show SMILES CN1C2COCC1CC(C2)OC(=O)c1cn(CCF)c2ccc(cc12)C#N |THB:10:8:1:3.5.4| Show InChI InChI=1S/C20H22FN3O3/c1-23-14-7-16(8-15(23)12-26-11-14)27-20(25)18-10-24(5-4-21)19-3-2-13(9-22)6-17(18)19/h2-3,6,10,14-16H,4-5,7-8,11-12H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.746	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221576 (US9303045, 62 | US9695195, 62) Show SMILES CN1C2CCC1CC(C2)NC(=O)c1nn(c2ccccc12)S(C)(=O)=O |THB:9:7:1:3.4| Show InChI InChI=1S/C17H22N4O3S/c1-20-12-7-8-13(20)10-11(9-12)18-17(22)16-14-5-3-4-6-15(14)21(19-16)25(2,23)24/h3-6,11-13H,7-10H2,1-2H3,(H,18,22)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.75	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221678 (US9303045, 190 | US9695195, 190) Show SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2ccnnc2)c2ccccc12 |THB:10:8:1:3.5.4| Show InChI InChI=1S/C21H23N5O2/c1-25-16-8-14(9-17(25)13-28-12-16)24-21(27)19-11-26(15-6-7-22-23-10-15)20-5-3-2-4-18(19)20/h2-7,10-11,14,16-17H,8-9,12-13H2,1H3,(H,24,27)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.75	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221603 (US9303045, 90 | US9695195, 90) Show SMILES CN1C2CCC1CC(C2)NC(=O)c1nn(CC(F)F)c2ccccc12 |THB:9:7:1:3.4| Show InChI InChI=1S/C18H22F2N4O/c1-23-12-6-7-13(23)9-11(8-12)21-18(25)17-14-4-2-3-5-15(14)24(22-17)10-16(19)20/h2-5,11-13,16H,6-10H2,1H3,(H,21,25)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.75	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221526 (US9303045, 10 | US9303045, 111 | US9695195, 111) Show SMILES CC(C)S(=O)(=O)n1cc(C(=O)NC2CC3COCC(C2)N3C)c2ccccc12 |TLB:11:12:20:15.17.16| Show InChI InChI=1S/C20H27N3O4S/c1-13(2)28(25,26)23-10-18(17-6-4-5-7-19(17)23)20(24)21-14-8-15-11-27-12-16(9-14)22(15)3/h4-7,10,13-16H,8-9,11-12H2,1-3H3,(H,21,24)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.770	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 3A (Homo sapiens (Human))	BDBM221554 (US9303045, 40 | US9695195, 40) Show SMILES CN1C2CCC1CC(C2)OC(=O)c1cn(CC(F)F)c2ccccc12 |THB:9:7:1:3.4| Show InChI InChI=1S/C19H22F2N2O2/c1-22-12-6-7-13(22)9-14(8-12)25-19(24)16-10-23(11-18(20)21)17-5-3-2-4-15(16)17/h2-5,10,12-14,18H,6-9,11H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	0.780	n/a	n/a	n/a	n/a	n/a	37
Takeda Pharmaceutical Company Limited US Patent					Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...				US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 162 total )  |  Next  |  Last  >>

Jump to: